This observation is consistent with findings in tumor models, where trametinib was shown to impair the priming of tumor-specific naive CD8 T cells while promoting the accumulation of Tpex CD8+TCF1+ by impairing their evolution into exhausted CD8+TCF1- cells.25 Here, TCF7 is linked to neoplasm.